- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03531372
Mipolixin® Compared to Poliprotect® in Moderate Functional Dyspepsia and Heartburn.
Efficacy and Safety of Mipolixin® Compared to Poliprotect ® in the Relief of Symptoms of Moderate Functional Dyspepsia and Heartburn: A Randomized, Double-blind, Parallel Group,Non-inferiority Clinical Study
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Albuñol, Spain, 18700
- CS Albuñol
-
El Prat De Llobregat, Spain, 08820
- CS Disset de Setembre
-
Madrid, Spain, 28006
- CS Montesa
-
Madrid, Spain, 28009
- CS Goya
-
Madrid, Spain, 28010
- Primary Care Centre Eloy Gonzalo
-
Madrid, Spain, 28019
- CS Comillas
-
Madrid, Spain, 28028
- CS Baviera
-
Parla, Spain, 28981
- Cs Las Américas
-
Parla, Spain, 28981
- CS San Blas
-
Parla, Spain, 28982
- CS Isabel II
-
Perales de Tajuña, Spain, 28540
- Consultorio Local Perales de Tajuña
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ability to provide informed consent, preferably in writing or, failing that, orally in front of a witness, before any study procedure is performed.
- Male and female patients aged 18 to 75 years old (inclusive).
Patients with symptoms of functional dyspepsia (according to the Rome IV criteria) of moderate severity (VAS score between 30 mm and 70 mm) and/or bothersome heartburn within 2 and 14 days prior to the screening/baseline visit.
o According to the current Rome IV diagnostic criteria, functional dyspepsia is defined as one or more of the following symptoms: postprandial fullness (classified as postprandial distress syndrome), early satiation (inability to finish a normal sized meal, also classified as postprandial distress syndrome), and epigastric pain or burning (classified as epigastric pain syndrome).
- Ability of the patients (according to the investigator's opinion) to comprehend the full nature and purpose of the study including possible risks and side effects.
- Patients who agree not to alter their diet in any way for the duration of the trial and to maintain it at steady state.
- Patients who agree not to make any major lifestyle changes during the trial.
- Willingness to comply with all the study procedures and schedule.
- Chronic therapies (if not related to the gastroenterological pathologies object of the study, according to the opinion of the investigator) are allowed, if the regimen is maintained stable during the whole study.
Exclusion Criteria:
Declines or unable to provide informed consent.
- Disease or health condition
- Patient presenting at least one of the following symptoms or conditions at screening: anemia, chronic gastrointestinal bleeding, progressive unintentional weight loss, epigastric mass, anorexia, persistent or recurrent vomiting, dysphagia or odynophagia, porphyria, hypophosphatemia, and/or cachexia.
- Patients presenting with at least of the following gastrointestinal conditions at screening: erosive GERD, Barrett's oesophagus or oesophageal stricture, active or healing gastroduodenal ulcer (except scars), history of gastric, duodenal or esophageal surgery, symptomatic gallstone, and/or other gastrointestinal disease such as gastroenteritis, inflammatory bowel disease, celiac disease and/or colorectal cancer.
- Patients with known malignancy disease, infectious disease or severe heart or pulmonary disease.
- Patients with known severe liver or kidney disease (AST/SGOT, ALT/SGPT >2 upper limits of normal, serum creatinine >1.5 mg/dl).
Patients with mental or metabolic disorders and any other disease that according to the physician can compromise the patient´s safety and/or patient´s study compliance.
- Treatments
- Patients receiving any treatment (pharmacological or medical device) for heartburn or dyspeptic symptoms within the last 14 days prior to randomization.
- Patients receiving any drugs that could affect symptoms or study evaluation such antacids, PPIs, H2RAs, prokinetics, and/or gastric mucosal protectants at baseline and/or taken within the last 14 days prior to randomization.
- Patients receiving any drugs that could affect symptoms or the study as antibiotics, NSAIDs, anticholinergics and/or cholinergic agents.
Note: Patients will be asked to avoid any drugs of the above mentioned since the beginning of the study (baseline visit) until the end of the study.
- Patients under triple therapy or eradication therapy against Helicobacter pylori.
- Patients planned for long-term new therapies with anti-anxiety agents, glucocorticosteroids and anti-inflammatory agents during study period.
- Known hypersensitive or intolerance to any components of the study medical devices.
Previous intake of any of the study medical devices.
- Other general conditions
- Patients who are unable to understand or are unwilling to sign an informed consent form.
- Unable or unwilling to complete all required screening and/or follow-up assessments.
- Unable to understand and complete self-administered scales/questionnaires planned to be used in the study.
- Participation in interventional research studies of investigational medicinal or device products (ongoing or terminated less than 30 days before screening)
- Patients with active alcohol or drug addiction or any other condition that, in the investigator's opinion, would interfere with their ability to comply with the study requirements.
- Patients with any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the patient or compliance with the protocol.
- Pregnant or nursing (lactating) women;
- Women of childbearing potential and sexually active: they must be willing to use at least one acceptable effective contraceptive measure (- progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action , - male or female condom with or without spermicide, - cap, diaphragm or sponge with spermicide). Pregnancy test will be performed at screening and at the final/premature withdrawal visit. The use of contraception in male patients is not required.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mipolixin®
Mipolixin® (Advanced Natural Antacid - AdNA)
|
1.55g chewable tablet 5 times a day for 2 weeks
Other Names:
|
Active Comparator: Poliprotect®
Poliprotect® (Neobianacid)
|
1.55 g chewable tablet 5 times a day for 2 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in overall symptom severity from baseline (day 0) to day 14 between the two study arms
Time Frame: Day 0 and Day 14
|
The primary endpoint is the change in the score of a visual analog scale (VAS) (from "no symptoms" to "overwhelming symptoms") used for evaluating overall symptom severity from baseline (day 0) to day 14 after treatment initiation, between the two study arms.
A decrease in VAS score of at least 30% is considered as a clinically meaningful improvement, and therefore subjects achieving a decrease ≥30% in this scale will be considered as responders.
The non-inferiority is considered demonstrated if the 95% confidence interval of the difference in the percentage of responders between both study arms lies within the non-inferior margin value defined of 20%.
|
Day 0 and Day 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Responders from baseline to day 3 and day 7
Time Frame: Day 0, Day 3 and Day 7
|
Percentage of responder patients (VAS score decrease of at least 30%) on the basis of the mean change in the overall symptom severity assessed by the VAS score from baseline to day 3 and day 7 in both study arms
|
Day 0, Day 3 and Day 7
|
Self-assessment severity of individual specific symtoms
Time Frame: Day 0, Day 1, Day 3, Day 7 and Day 14
|
Comparison between Mipolixin® and Poliprotect® in the mean change of the score of the self-assessed severity of individual specific symtoms (bothersome postprandial fullness, bothersome early satiation, bothersome epigastric pain, bothersome epigastric burning, and bothersome heartburn) rated on a 100 mm VAS (from "no symptoms" to "overwhelming symptoms") from baseline to 1 3, 7 and 14 days after treatment initiation.
|
Day 0, Day 1, Day 3, Day 7 and Day 14
|
Change in the score of GOS scale from baseline to day 1
Time Frame: Day 0 and Day 14
|
Change in the score of GOS ( Global Overall Symptom) scale from baseline to day 14 in both study arms.
A decrease in GOS score ≥2 is considered as a clinically meaningful improvement, and therefore subjects achieving a decrease in overall severity score ≥2 from baseline in this scale will be considered as responders.
|
Day 0 and Day 14
|
Incidence of AEs during study treatment
Time Frame: Day 0 to Day 14
|
Incidence and type of adverse events (AEs) and serious adverse events (SAEs) reported during study treatment.
|
Day 0 to Day 14
|
Incidence of AEs and clinical findings during study period
Time Frame: Day 0 to Day 28
|
Safety will be assessed on the basis of all AEs experienced during study treatment and all observed and volunteered AEs and abnormal findings on physical examination, including vital signs throughout the study.
|
Day 0 to Day 28
|
Patient satisfaction (treatment administration)
Time Frame: Day 3, Day 7 and Day 14
|
Patient level of satisfaction in terms of treatment administration/posology will be assessed by means of specific questions about patient level of satisfaction after the 2-week treatment period.
The response will be scored on a 4-point Likert scale from 0 to 4, as follows: 1 = "very satisfied", 2 = "quite satisfied", 3 = "somewhat satisfied", 4 = "not satisfied".
|
Day 3, Day 7 and Day 14
|
Patient satisfaction (taste)
Time Frame: Day 3, Day 7 and Day 14
|
Patient level of satisfaction in terms of chewable tablets taste will be assessed by means of specific questions about patient level of satisfaction after the 2-week treatment period.
The response will be scored on a 4-point Likert scale from 0 to 4, as follows: 1 = "very satisfied", 2 = "quite satisfied", 3 = "somewhat satisfied", 4 = "not satisfied".
|
Day 3, Day 7 and Day 14
|
Treatment compliance
Time Frame: Day 0 to Day 14
|
Treatment compliance will be evaluated by performing the IP accountability.
This data will be corroborated with the information recorded in the patient diary concerning the daily administered and missed doses.
|
Day 0 to Day 14
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ABO-NB-SEM-17
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dyspepsia
-
King Chulalongkorn Memorial HospitalRecruiting
-
Wuhan Central HospitalNot yet recruiting
-
Dong-A ST Co., Ltd.Not yet recruitingFunctional DyspepsiaKorea, Republic of
-
Universitaire Ziekenhuizen KU LeuvenRecruiting
-
Universitaire Ziekenhuizen KU LeuvenRecruiting
-
Zeria PharmaceuticalRecruitingFunctional DyspepsiaJapan
-
Hong Kong Baptist UniversityXiyuan Hospital of China Academy of Chinese Medical SciencesRecruitingFunctional DyspepsiaHong Kong
-
Seoul National University HospitalCompletedFunctional DyspepsiaKorea, Republic of
-
Wonju Severance Christian HospitalCompletedFunctional DyspepsiaKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.CompletedFunctional DyspepsiaKorea, Republic of
Clinical Trials on Mipolixin®
-
Dong-A ST Co., Ltd.CompletedFunctional DyspepsiaKorea, Republic of
-
Galderma R&DCompletedAtopic DermatitisPhilippines, China
-
Chong Kun Dang PharmaceuticalCompleted
-
Chung-Ang University Hosptial, Chung-Ang University...UnknownFunctional DyspepsiaKorea, Republic of
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Diphtheria | PolioUnited States
-
Amir AzarpazhoohInstitut Straumann AGCompletedPeriodontal Inflammation | Crown LengtheningCanada
-
Novartis PharmaceuticalsCompletedPulmonary Disease, Chronic Obstructive (COPD)Argentina
-
GuerbetCompletedPrimary Brain TumorColombia, Korea, Republic of, United States, Mexico
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussisUnited States